Osteoporosis

Overview

Osteoporosis is a skeletal disease characterized by reduced bone mineral density and deterioration of bone microarchitecture, leading to increased bone fragility and fracture risk. The word itself means "porous bone" — and under a microscope, osteoporotic bone shows the enlarged holes and weakened struts that make fractures more likely even from minor falls or, in severe cases, everyday activity.

Osteoporosis is often called a silent disease because bone loss occurs without pain or symptoms. Most people are unaware they have it until a fracture occurs — commonly of the hip, spine, or wrist. It is one of the most common chronic conditions worldwide, affecting an estimated 200 million people globally, with postmenopausal women at highest risk.

The condition is detected and monitored through bone density testing (DEXA scan) and supported by a panel of blood and urine markers that assess bone turnover, calcium metabolism, vitamin D status, and hormonal balance.

---

How Bone Density Works

Bone is living tissue that undergoes continuous remodeling throughout life. Two types of cells govern this process: osteoblasts, which build new bone, and osteoclasts, which break down old bone. In healthy bone, this cycle is balanced. In osteoporosis, resorption (breakdown) outpaces formation, resulting in progressive bone loss.

Peak bone mass is typically reached in the late 20s to early 30s. After that, bone density gradually declines in both men and women. The rate of loss accelerates sharply in women during the years around menopause, when estrogen — which actively suppresses bone resorption — falls rapidly. In men, bone loss is slower and more gradual but increases with declining testosterone and estradiol.

Bone mineral density is measured using a T-score, which compares your density to that of a healthy young adult:

• T-score above −1.0: Normal bone density
• T-score between −1.0 and −2.5: Osteopenia (low bone mass — a precursor to osteoporosis)
• T-score at or below −2.5: Osteoporosis
• T-score at or below −2.5 with a fragility fracture: Severe osteoporosis

---

Causes and Risk Factors

Osteoporosis develops from a combination of factors that tip the bone remodeling balance toward excessive loss.

Hormonal causes

• Menopause and estrogen deficiency — the single most important risk factor in women. Estrogen directly inhibits osteoclast activity. When it falls at menopause, bone resorption accelerates significantly.
• Low estradiol in men — research has established that estradiol, not testosterone, is the dominant hormone protecting male bone mass. Men with chronically low estradiol lose bone at rates comparable to postmenopausal women.
• Hypogonadism — low sex hormone production in either sex
• Hyperthyroidism — excess thyroid hormone accelerates bone turnover
• Hyperparathyroidism — elevated PTH drives excessive bone resorption
• Hyperprolactinemia — suppresses sex hormone production
• Cushing's syndrome — excess cortisol inhibits bone formation

Nutritional and lifestyle causes

• Vitamin D deficiency — impairs calcium absorption and bone mineralization
• Low calcium intake over many years
• Smoking — directly toxic to osteoblasts
• Excessive alcohol intake
• Physical inactivity — weight-bearing exercise stimulates bone formation
• Very low body weight or eating disorders

Medical and medication-related causes

• Long-term corticosteroid use (glucocorticoid-induced osteoporosis is the most common secondary form)
• Malabsorption conditions (celiac disease, Crohn's disease, gastric bypass)
• Chronic kidney disease
• Rheumatoid arthritis and other inflammatory conditions
• Certain anticonvulsants, aromatase inhibitors, and androgen deprivation therapy for prostate cancer

Non-modifiable risk factors

• Female sex
• Advancing age
• White or Asian ethnicity (higher genetic risk)
• Family history of osteoporosis or hip fracture
• Small body frame

---

Symptoms of Osteoporosis

Osteoporosis itself causes no symptoms until a fracture occurs. This is why it is often described as a "silent" condition and why lab-based screening and bone density testing are essential — not optional — for at-risk individuals.

When fractures do occur, they most commonly affect:

• Vertebrae (spine) — often occurring without a fall, causing sudden back pain, loss of height, or a stooped posture (kyphosis)
• Hip — typically from a fall; associated with significant morbidity and mortality in older adults
• Wrist (distal radius) — often from falling onto an outstretched hand
• Shoulder, ribs, and pelvis — less common but may occur in severe osteoporosis

A fragility fracture — one occurring from a fall from standing height or less, or from minimal trauma — is itself diagnostic of severe osteoporosis regardless of the measured T-score.

---

How Osteoporosis Is Diagnosed

Diagnosis is based on a combination of imaging, blood tests, and clinical assessment.

DEXA scan (Dual-energy X-ray absorptiometry)

The gold-standard test for measuring bone mineral density at the hip and lumbar spine. It is recommended for all women over 65, postmenopausal women under 65 with risk factors, men over 70, and anyone who has had a fragility fracture.

Blood and urine markers

Lab testing is used to identify underlying causes of bone loss, assess nutritional status, measure bone turnover activity, and rule out secondary conditions. Key markers include:

• Calcium (total and ionized) — to assess calcium metabolism and exclude hyperparathyroidism
• Vitamin D (25-hydroxyvitamin D) — deficiency is a major modifiable risk factor
• PTH (Parathyroid Hormone) — elevated in hyperparathyroidism, which drives bone resorption
• Phosphorus — regulated alongside calcium in bone metabolism
• Alkaline Phosphatase (ALP) — elevated during active bone formation or fracture healing
• CTX (C-telopeptide crosslinks) — a marker of bone resorption; elevated in high-turnover bone loss
• P1NP (Procollagen type 1 N-terminal propeptide) — a marker of bone formation; used to monitor anabolic therapy response
• Estradiol — particularly important in men and premenopausal women with unexplained bone loss
• Testosterone and SHBG — in men with suspected hypogonadism
• TSH — to exclude hyperthyroidism
• FSH and LH — to assess menopausal status or hypogonadism
• Cortisol — to exclude Cushing's syndrome
• CBC and metabolic panel — to screen for malabsorption, inflammation, and organ dysfunction

Tracking these markers over time — alongside DEXA results — provides a far more complete picture of bone health than a single measurement. Platforms like HealthMatters.io allow you to upload, visualize, and monitor these markers longitudinally, making it easier to understand trends and treatment response.

---

Osteoporosis in Men

Osteoporosis is often perceived as a women's disease, but approximately one in five men over 50 will experience an osteoporotic fracture. Men with osteoporosis are less likely to be diagnosed, less likely to be treated, and have higher mortality after hip fracture than women.

In men, secondary causes are more common than in women and should always be investigated. The most important hormonal driver in men is estradiol deficiency, not testosterone deficiency — estradiol is the principal bone-protective sex hormone in males as well as females. Low testosterone contributes indirectly, primarily by reducing the substrate for aromatization to estradiol.

Additional male-specific risk factors include androgen deprivation therapy (ADT) for prostate cancer, heavy alcohol use, and glucocorticoid therapy.

---

Treatment and Management

Treatment depends on fracture risk, T-score, underlying cause, and individual health status. The goal is to reduce fracture risk — not just to improve a number on a scan.

Lifestyle and nutritional foundations

• Calcium: 1000–1200 mg/day total (food plus supplement if needed)
• Vitamin D: Maintain 25-hydroxyvitamin D above 50 nmol/L (20 ng/mL); many guidelines target 75+ nmol/L (30+ ng/mL)
• Weight-bearing and resistance exercise: Stimulates osteoblast activity and improves balance, reducing fall risk
• Fall prevention: Home safety assessment, balance training, review of medications that increase fall risk
• Smoking cessation and reduced alcohol intake

Pharmacological treatment

• Bisphosphonates (alendronate, risedronate, zoledronic acid) — first-line antiresorptive therapy; reduce osteoclast activity
• Denosumab — a monoclonal antibody that inhibits RANKL, suppressing bone resorption; given by injection every 6 months
• Hormone replacement therapy (HRT) — effective for bone preservation in postmenopausal women; decision balances benefits against individual risk profile
• Teriparatide / Abaloparatide — anabolic agents (PTH analogs) that stimulate bone formation; used in severe cases
• Romosozumab — a newer dual-action agent that both builds bone and reduces resorption

Treating secondary causes

When osteoporosis is driven by an identifiable condition — vitamin D deficiency, hyperparathyroidism, hypogonadism, or corticosteroid use — addressing that cause is a central part of management. Lab-guided treatment of these underlying drivers can substantially reduce bone loss without additional medication in some cases.

---

Monitoring Treatment Response

Response to osteoporosis treatment is tracked through:

• Repeat DEXA scan (typically every 1–2 years)
• Bone turnover markers (CTX for resorption, P1NP for formation) — change within weeks to months, earlier than DEXA
• Vitamin D and calcium levels — to confirm nutritional adequacy
• Continued assessment of fracture occurrence

Bone turnover markers are particularly useful for monitoring because they reflect biological response to treatment months before a DEXA scan can detect density changes. A significant drop in CTX within 3–6 months of starting antiresorptive therapy, for example, confirms the medication is working.

---

Summary

Osteoporosis is a common, underdiagnosed, and largely preventable condition that causes progressive bone loss and dramatically increases fracture risk. It develops silently over years before a fracture brings it to attention — which makes proactive testing essential for at-risk individuals.

Effective management requires more than a single DEXA scan. It involves identifying and treating underlying hormonal and nutritional drivers, lifestyle modification, and in many cases pharmacological therapy guided by bone turnover markers and repeat imaging. Estradiol plays a central role in bone protection in both women and men — making it one of the most important lab markers in any comprehensive osteoporosis workup.

Tracking bone-related biomarkers — including vitamin D, calcium, PTH, estradiol, and bone turnover markers — over time is critical for understanding both the severity of bone loss and the response to treatment.

---

FAQ: Osteoporosis

What is osteoporosis?

Osteoporosis is a disease in which bone mineral density decreases and bone microarchitecture deteriorates, making bones fragile and prone to fracture. It is most common in postmenopausal women but affects men and women of all ages. It is often called a silent disease because bone loss occurs without symptoms until a fracture happens.

What causes osteoporosis?

The most common cause is estrogen deficiency after menopause, which removes a key brake on bone resorption. In men, low estradiol (not just low testosterone) is the dominant hormonal driver of bone loss. Other causes include vitamin D and calcium deficiency, long-term corticosteroid use, hyperparathyroidism, hyperthyroidism, malabsorption conditions, smoking, excessive alcohol, and physical inactivity.

What are the symptoms of osteoporosis?

Osteoporosis itself causes no symptoms — bone loss is painless. Symptoms appear when a fracture occurs. Common fracture sites include the spine (causing sudden back pain, height loss, or stooped posture), the hip, and the wrist. A fracture from a minor fall or everyday activity — called a fragility fracture — is itself a sign of significant bone loss.

How is osteoporosis diagnosed?

The primary diagnostic test is a DEXA scan, which measures bone mineral density at the hip and spine and generates a T-score. A T-score at or below −2.5 indicates osteoporosis; between −1.0 and −2.5 indicates osteopenia. Blood tests are used to identify underlying causes and nutritional deficiencies, and include vitamin D, calcium, PTH, estradiol, thyroid markers, and bone turnover markers.

What is a T-score and what does it mean?

A T-score compares your bone mineral density to that of a healthy young adult at peak bone mass. A T-score above −1.0 is normal. Between −1.0 and −2.5 is osteopenia (low bone mass). At or below −2.5 is osteoporosis. The lower the T-score, the higher the fracture risk.

What blood tests are done for osteoporosis?

Key blood and urine tests include 25-hydroxyvitamin D (vitamin D status), calcium, PTH (parathyroid hormone), phosphorus, alkaline phosphatase, CTX (bone resorption marker), P1NP (bone formation marker), estradiol, testosterone (in men), TSH, FSH, and a basic metabolic panel. These tests help identify the cause of bone loss and guide treatment.

What is the role of estradiol in osteoporosis?

Estradiol is the primary sex hormone protecting bone mass in both women and men. It directly suppresses osteoclasts — the cells that break down bone. In women, the rapid decline in estradiol at menopause is the main trigger for accelerated bone loss. In men, research has confirmed that estradiol (not testosterone) is the dominant bone-protective hormone, and men with low estradiol lose bone at rates comparable to postmenopausal women.

What is the difference between osteoporosis and osteopenia?

Osteopenia refers to bone mineral density that is lower than normal but not low enough to meet the threshold for osteoporosis — a T-score between −1.0 and −2.5. It is a risk factor for osteoporosis rather than a disease in itself. People with osteopenia have elevated fracture risk compared to those with normal density but lower risk than those with osteoporosis.

Can osteoporosis be reversed?

Bone density can be improved with treatment — anabolic agents like teriparatide and romosozumab actively build bone, while antiresorptive therapies stabilize and modestly increase density over time. Addressing nutritional deficiencies and underlying hormonal causes can also produce meaningful improvement. Complete reversal to normal bone density is generally not achievable in established osteoporosis, but fracture risk can be substantially reduced.

How is osteoporosis treated?

Treatment combines lifestyle measures (adequate calcium, vitamin D, weight-bearing exercise, fall prevention), pharmacological therapy (bisphosphonates, denosumab, hormone replacement therapy, or anabolic agents depending on severity and individual risk), and treatment of any underlying cause. The goal is fracture prevention, not just improvement in bone density numbers.

Does vitamin D deficiency cause osteoporosis?

Vitamin D deficiency impairs calcium absorption and bone mineralization and is a major modifiable risk factor for osteoporosis. Severe deficiency causes a related but distinct condition called osteomalacia (softening of the bone). Correcting vitamin D deficiency is a foundational step in osteoporosis prevention and treatment.

Is osteoporosis only a women's disease?

No. While postmenopausal women are at highest risk, approximately one in five men over 50 will experience an osteoporotic fracture. Men with osteoporosis are significantly underdiagnosed and undertreated. Male osteoporosis is often secondary to identifiable causes — most commonly low estradiol, hypogonadism, long-term corticosteroid use, or heavy alcohol use — making a full hormonal workup especially important in men.

What is a fragility fracture?

A fragility fracture is one that occurs from low-energy trauma — typically a fall from standing height or less, or minimal mechanical force. In a person with healthy bones, such forces would not cause a fracture. A fragility fracture is itself diagnostic of severe osteoporosis, regardless of what a bone density scan shows, and should always prompt a full osteoporosis evaluation and treatment.

How is osteoporosis monitored over time?

Response to treatment is tracked with repeat DEXA scans (typically every 1–2 years) and bone turnover markers — CTX (resorption) and P1NP (formation). Bone turnover markers respond to therapy within weeks to months, far earlier than DEXA changes, and are useful for confirming that treatment is working between scans. Vitamin D and calcium levels should also be monitored to ensure nutritional targets are maintained.